Efficacy of acarbose monotherapy in patients with type 2 diabetes: A double-blind study conducted in general practice

Endocrinology and Metabolism, Supplement

Volumn 3, Issue 4, 1996, Pages 275-280

  Braun, Dieter ^a   Schönherr, Uwe ^a   Mitzkat, Hans Juergen ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COLIC; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FLATULENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; METEORISM; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029830298     PISSN: 1074939X     EISSN: 20935978     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insuline resistance in essential hypertension. N. Engl. J. Med. 1987; 317: 350-357.
2. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
3. Goodman AM. Efficacy and safety of metformin in Type 2 diabetes: results of a multicentre trial. Diabetes 1993; 42 (Suppl. 1): 57A.
4. Hotta N, Kakuta H, Sano T, Matsumae H, Yamada H, Kitazawa S, Sakamoto N. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study. Diabet. Med. 1993; 10: 134-138.
5. Puls W. A new approach to the treatment of diabetes, obesity and hyperlipoproteinaemia. Naturwissenschaften 1977; 64: 536-37.
6. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, Fücker K. Therapeutic potential of acarbose as first-line drug in Type 2 diabetes insufficiently treated with diet alone. Diabetes Care 1991; 14: 732-37.
7. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients. Diabetes Care 1994; 17: 561-66.
8. Aubeli R, Boehme K, Berchtold P. One-year acarbose treatment of diabetic out-patients. Multicentre study part 2: efficacy. In: Creutzfeldt W, ed. Proceedings of the First International Symposium on Acarbose. Amsterdam: Exerpta Medica, 1981; 363-366.
9. Sachse E, Mäser E, Laube H, Federlin K. Effect of long-term acarbose therapy on the metabolic situation of diabetic patients treated with sulphonylureas. In: Creutzfeldt W, ed. Proceedings of the First International Symposium on Acarbose. Amsterdam: Exerpta Medica, 1981; 298-304.
10. Kritchevsky D, Tepper SA, Davidson LM, Klurfeld DM. Influence of acarbose (a glucosidase inhibitor) on experimental atherosclerosis in the rabbit. Artery 1990; 17: 170-175.
11. Tulp OL, Abdollahi A, Stevens C, Schnitzer-Polokoff R. The effect of the intestinal glucosidase inhibitor, acarbose, on cholesterogenesis in corpulent rats. Comp. Biochem. Physiol. 1991; 100: 763-768.
12. Baron AD, Eckel RH, Schmeiser L, Koltermann OG. The effect of short-term α-glucosidase inhibition on carbohydrate and lipid metabolism in Type 2 (non-insulin-dependent) diabetic patients. Metabolism 1987; 36: 409-415.
13. Reaven GM, Lardinois CK, Greenfield MS, Schwartz HC, Vreman HJ. Effect of acarbose on carbohydrate and lipid metabolism in Type 2 diabetes patients poorly controlled by sulphonylureas. Diabetes Care 1990; 13 (Suppl. 3): 32-36.
14. Walter-Sack IE, Wolfram G, Zöllner N. Effects of acarbose on serum lipoproteins in healthy individuals during prolonged administration of a fibre-free formula diet. Ann. Nutr. Metab. 1989; 33: 100-107.
15. Spengler M, Cagatay M. Bewertung der Wirksamkeit und Verträglichkeit von Acarbose durch Anwendungsbeobachtung [Post-marketing surveillance of the efficacy and safety of acarbose]. Diabetes und Stoffwechsel 1992; 1: 218-222.